Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2145

1.

Structure-based Discovery of a new Protein-Aggregation Breaking Excipient.

Tosstorff A, Svilenov H, Peters GHJ, Harris P, Winter G.

Eur J Pharm Biopharm. 2019 Sep 12. pii: S0939-6411(19)30481-3. doi: 10.1016/j.ejpb.2019.09.010. [Epub ahead of print]

PMID:
31521717
2.

Combination therapies of Artemisinin and its derivatives as a viable approach for future cancer treatment.

Kumar MS, Yadav TT, Khair RR, Peters GJ, Yergeri MC.

Curr Pharm Des. 2019 Sep 2. doi: 10.2174/1381612825666190902155957. [Epub ahead of print]

PMID:
31475891
3.

The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.

El Hassouni B, Granchi C, Vallés-Martí A, Supadmanaba IGP, Bononi G, Tuccinardi T, Funel N, Jimenez CR, Peters GJ, Giovannetti E, Minutolo F.

Semin Cancer Biol. 2019 Aug 21. pii: S1044-579X(19)30180-4. doi: 10.1016/j.semcancer.2019.08.025. [Epub ahead of print] Review.

PMID:
31445217
4.

Breastfeeding during R-CHOP chemotherapy: please abstain!

Codacci-Pisanelli G, Honeywell RJ, Asselin N, Bellettini G, Peters GJ, Giovannetti E, Peccatori FA.

Eur J Cancer. 2019 Aug 19;119:107-111. doi: 10.1016/j.ejca.2019.07.012. [Epub ahead of print] No abstract available.

PMID:
31437753
5.

A retrospective analysis of the pathogens in the airways of patients with primary ciliary dyskinesia.

Roden L, Görlich D, Omran H, Peters G, Große-Onnebrink J, Kahl BC.

Respir Med. 2019 Sep;156:69-77. doi: 10.1016/j.rmed.2019.08.009. Epub 2019 Aug 15.

PMID:
31437650
6.

Four steps for revealing and adjusting the 3D structure of aptamers in solution by small-angle X-ray scattering and computer simulation.

Tomilin FN, Moryachkov R, Shchugoreva I, Zabluda VN, Peters G, Platunov M, Spiridonova V, Melnichuk A, Atrokhova A, Zamay SS, Ovchinnikov SG, Zamay GS, Sokolov A, Zamay TN, Berezovski MV, Kichkailo AS.

Anal Bioanal Chem. 2019 Oct;411(25):6723-6732. doi: 10.1007/s00216-019-02045-0. Epub 2019 Aug 8.

PMID:
31396648
7.

Outcome Predictors of SD-OCT-Driven Intravitreal Ranibizumab in Choroidal Neovascularization due to Myopia.

Guichard MM, Peters G, Tuerksever C, Pruente C, Hatz K.

Ophthalmologica. 2019 Aug 6:1-8. doi: 10.1159/000501040. [Epub ahead of print]

PMID:
31387095
8.

Pedometer-measured physical activity among emergency physicians during shifts.

Peters GA, Wong ML, Sanchez LD.

Am J Emerg Med. 2019 Jul 17:158349. doi: 10.1016/j.ajem.2019.07.019. [Epub ahead of print]

PMID:
31378411
9.

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.

Zhang L, Yan X, Nandy P, Willmann S, Fox KAA, Berkowitz SD, Sharma A, Hermanowski-Vosatka A, Schmidt S, Weitz JI, Garmann D, Peters G.

Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719863641. doi: 10.1177/1753944719863641.

10.

Purulent bacterial pericarditis from Staphylococcus aureus.

Kaye A, Peters GA, Joseph JW, Wong ML.

Clin Case Rep. 2019 May 28;7(7):1331-1334. doi: 10.1002/ccr3.2224. eCollection 2019 Jul.

11.

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines.

Noordhuis P, Laan AC, van de Born K, Honeywell RJ, Peters GJ.

Int J Mol Sci. 2019 Jul 24;20(15). pii: E3619. doi: 10.3390/ijms20153619.

12.

Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells.

Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E.

Anticancer Res. 2019 Jul;39(7):3615-3620. doi: 10.21873/anticanres.13509.

PMID:
31262887
13.

Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer.

El Hassouni B, Infante J, Mantini G, Ricci C, Funel N, Giovannetti E, Peters GJ.

Anticancer Res. 2019 Jul;39(7):3609-3614. doi: 10.21873/anticanres.13508.

PMID:
31262886
14.

From 'Targeted Therapy' to Targeted Therapy.

Peters GJ.

Anticancer Res. 2019 Jul;39(7):3341-3345. doi: 10.21873/anticanres.13476. Review.

PMID:
31262854
15.

To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.

El Hassouni B, Mantini G, Li Petri G, Capula M, Boyd L, Weinstein HNW, Vallés-Marti A, Kouwenhoven MCM, Giovannetti E, Westerman BA, Peters GJ; EORTC PAMM Group.

Anticancer Res. 2019 Jul;39(7):3303-3309. doi: 10.21873/anticanres.13472. Review.

PMID:
31262850
16.

Studies of the oligomerisation mechanism of a cystatin-based engineered protein scaffold.

Zalar M, Indrakumar S, Levy CW, Tunnicliffe RB, Peters GHJ, Golovanov AP.

Sci Rep. 2019 Jun 21;9(1):9067. doi: 10.1038/s41598-019-45565-6.

17.

In Situ WAXD and SAXS during Tensile Deformation Of Moulded and Sintered Polyamide 12.

Paolucci F, Govaert L, Peters G.

Polymers (Basel). 2019 Jun 5;11(6). pii: E1001. doi: 10.3390/polym11061001.

18.

Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.

Hart RG, Veltkamp RC, Sheridan P, Sharma M, Kasner SE, Bangdiwala SI, Ntaios G, Shoamanesh A, Ameriso SF, Toni D, Czlonkowska A, Lindgren A, Hankey GJ, Perera KS, Shuaib A, Coutts SB, Gagliardi RJ, Berkowitz SD, Mundl H, Peters G, Connolly SJ; NAVIGATE ESUS Investigators.

J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2273-2279. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.014. Epub 2019 May 31.

PMID:
31160218
19.

Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.

Van Den Borg R, Leonetti A, Tiseo M, Giovannetti E, Peters GJ.

Expert Rev Anticancer Ther. 2019 Jun;19(6):461-471. doi: 10.1080/14737140.2019.1624530. Epub 2019 May 31.

PMID:
31148500
20.

The prevalence of Staphylococcus aureus with mucoid phenotype in the airways of patients with cystic fibrosis-A prospective study.

Lennartz FE, Schwartbeck B, Dübbers A, Große-Onnebrink J, Kessler C, Küster P, Schültingkemper H, Peters G, Kahl BC.

Int J Med Microbiol. 2019 Jul;309(5):283-287. doi: 10.1016/j.ijmm.2019.05.002. Epub 2019 May 11.

PMID:
31122879
21.

Application of interpretable artificial neural networks to early monoclonal antibodies development.

Gentiluomo L, Roessner D, Augustijn D, Svilenov H, Kulakova A, Mahapatra S, Winter G, Streicher W, Rinnan Å, Peters GHJ, Harris P, Frieß W.

Eur J Pharm Biopharm. 2019 Aug;141:81-89. doi: 10.1016/j.ejpb.2019.05.017. Epub 2019 May 18.

PMID:
31112768
22.

Conformational Stability Study of a Therapeutic Peptide Plectasin Using Molecular Dynamics Simulations in Combination with NMR.

Indrakumar S, Zalar M, Pohl C, Nørgaard A, Streicher W, Harris P, Golovanov AP, Peters GHJ.

J Phys Chem B. 2019 Jun 13;123(23):4867-4877. doi: 10.1021/acs.jpcb.9b02370. Epub 2019 May 31.

PMID:
31099578
23.

Rethinking gut microbiome residency and the Enterobacteriaceae in healthy human adults.

Martinson JNV, Pinkham NV, Peters GW, Cho H, Heng J, Rauch M, Broadaway SC, Walk ST.

ISME J. 2019 Sep;13(9):2306-2318. doi: 10.1038/s41396-019-0435-7. Epub 2019 May 14.

PMID:
31089259
24.

Combining in Silico Tools with Multicriteria Analysis for Alternatives Assessment of Hazardous Chemicals: A Case Study of Decabromodiphenyl Ether Alternatives.

Zheng Z, Peters GM, Arp HPH, Andersson PL.

Environ Sci Technol. 2019 Jun 4;53(11):6341-6351. doi: 10.1021/acs.est.8b07163. Epub 2019 May 23.

PMID:
31081616
25.

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.

Biochem Pharmacol. 2019 Aug;166:128-138. doi: 10.1016/j.bcp.2019.05.014. Epub 2019 May 10.

PMID:
31078602
26.

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells.

Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Löhr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E.

Cancers (Basel). 2019 May 8;11(5). pii: E638. doi: 10.3390/cancers11050638.

27.

Effect of Thermal History and Shear on the Viscoelastic Response of iPP Containing an Oxalamide-Based Organic Compound.

Wilsens CHRM, Hawke LGD, de Kort GW, Saidi S, Roy M, Leoné N, Hermida-Merino D, Peters GWM, Rastogi S.

Macromolecules. 2019 Apr 9;52(7):2789-2802. doi: 10.1021/acs.macromol.8b02612. Epub 2019 Mar 21.

28.

Structure-Properties Relations for Polyamide 6, Part 2: Influence of Processing Conditions during Injection Moulding on Deformation and Failure Kinetics.

Parodi E, Peters GWM, Govaert LE.

Polymers (Basel). 2018 Jul 16;10(7). pii: E779. doi: 10.3390/polym10070779.

29.
30.

Solution structures of long-acting insulin analogues and their complexes with albumin.

Ryberg LA, Sønderby P, Barrientos F, Bukrinski JT, Peters GHJ, Harris P.

Acta Crystallogr D Struct Biol. 2019 Mar 1;75(Pt 3):272-282. doi: 10.1107/S2059798318017552. Epub 2019 Feb 26.

PMID:
30950398
31.

Energy- and conformer-dependent excited-state relaxation of an E/Z photoswitchable thienyl-ethene.

Young JD, Honick CR, Zhou J, Pitts CR, Ghorbani F, Peters GM, Lectka T, Tovar JD, Bragg AE.

Phys Chem Chem Phys. 2019 Jul 14;21(26):14440-14452. doi: 10.1039/c9cp01226e. Epub 2019 Mar 28.

PMID:
30920561
32.

RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.

Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim E, Lee YB, Kim DJ, Peters GJ.

Expert Opin Investig Drugs. 2019 Apr;28(4):311-322. doi: 10.1080/13543784.2019.1583742. Epub 2019 Mar 16. Review.

PMID:
30879349
33.

Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases.

Frigerio B, Bizzoni C, Jansen G, Leamon CP, Peters GJ, Low PS, Matherly LH, Figini M.

J Exp Clin Cancer Res. 2019 Mar 12;38(1):125. doi: 10.1186/s13046-019-1123-1.

34.

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?

Peters GJ, Giovannetti E, Honeywell RJ, Ciccolini J.

Br J Clin Pharmacol. 2019 Jun;85(6):1213-1214. doi: 10.1111/bcp.13921. Epub 2019 Apr 23. No abstract available.

35.

Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.

Jaramillo AC, Cloos J, Lemos C, Stam RW, Kaspers GJL, Jansen G, Peters GJ.

Leuk Res. 2019 Apr;79:45-51. doi: 10.1016/j.leukres.2019.02.008. Epub 2019 Feb 23.

PMID:
30849662
36.

E-drug delivery: a futuristic approach.

Yadav KS, Kapse-Mistry S, Peters GJ, Mayur YC.

Drug Discov Today. 2019 Apr;24(4):1023-1030. doi: 10.1016/j.drudis.2019.02.005. Epub 2019 Feb 19. Review.

PMID:
30794860
37.

Progestin therapy to prevent preterm birth: History and effectiveness of current strategies and development of novel approaches.

Mesiano SA, Peters GA, Amini P, Wilson RA, Tochtrop GP, van Den Akker F.

Placenta. 2019 Apr;79:46-52. doi: 10.1016/j.placenta.2019.01.018. Epub 2019 Jan 28. Review.

PMID:
30745115
38.

Authors' reply.

Verhofstadt M, Chambaere K, Thienpont L, Peters GY.

Br J Psychiatry. 2018 Mar;212(3):183-184. doi: 10.1192/bjp.2018.17. No abstract available.

PMID:
30741143
39.

Authors' reply.

Verhofstadt M, Chambaere K, Audenaert K, Thienpont L, Peters GY.

Br J Psychiatry. 2018 Apr;212(4):248. doi: 10.1192/bjp.2018.48. No abstract available.

PMID:
30741139
40.

Best Practices From the APDR: Improving Medical Student Exposure to Interventional Radiology.

Goldman DT, Peters GL, Fischman AM, Vatakencherry GG, Bream PR Jr, Martin JG, Newsome JM, Bercu ZL, Schacht MA, Johnson KS, Milburn JM, Ong S, Kalia V, England E, Heitkamp DE.

Acad Radiol. 2018 Jun;25(6):789-791. doi: 10.1016/j.acra.2017.11.021. Epub 2018 Jan 19. No abstract available.

PMID:
30691774
41.

Migraine overview and summary of current and emerging treatment options.

Peters GL.

Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34.

42.

Pendant Photochromic Conjugated Polymers Incorporating a Highly Functionalizable Thieno[3,4- b]thiophene Switching Motif.

Peters GM, Tovar JD.

J Am Chem Soc. 2019 Feb 20;141(7):3146-3152. doi: 10.1021/jacs.8b12617. Epub 2019 Feb 6.

PMID:
30672284
43.

DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.

Honeywell RJ, Sarkisjan D, Kristensen MH, de Klerk DJ, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2018;37(12):696-708. doi: 10.1080/15257770.2018.1498516. Epub 2019 Jan 19.

PMID:
30663502
44.

Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.

Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2018;37(12):666-678. doi: 10.1080/15257770.2018.1508692. Epub 2019 Jan 19.

PMID:
30663496
45.

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.

Rovithi M, Gerritse SL, Honeywell RJ, Ten Tije AJ, Ruijter R, Peters GJ, Voortman J, Labots M, Verheul HMW.

J Clin Oncol. 2019 Feb 10;37(5):411-418. doi: 10.1200/JCO.18.00725. Epub 2018 Dec 26.

46.

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E.

EBioMedicine. 2019 Jan;39:215-225. doi: 10.1016/j.ebiom.2018.12.025. Epub 2018 Dec 20.

47.

Systematic literature review on which maternal alcohol behaviours are related to fetal alcohol spectrum disorders (FASD).

Roozen S, Peters GY, Kok G, Townend D, Nijhuis J, Koek G, Curfs L.

BMJ Open. 2018 Dec 19;8(12):e022578. doi: 10.1136/bmjopen-2018-022578.

48.

Self-Interaction of Human Serum Albumin: A Formulation Perspective.

Sønderby P, Bukrinski JT, Hebditch M, Peters GHJ, Curtis RA, Harris P.

ACS Omega. 2018 Nov 30;3(11):16105-16117. doi: 10.1021/acsomega.8b02245. Epub 2018 Nov 28.

49.

Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis.

Knaack D, Idelevich EA, Schleimer N, Molinaro S, Kriegeskorte A, Peters G, Becker K.

Diagn Microbiol Infect Dis. 2019 Apr;93(4):362-368. doi: 10.1016/j.diagmicrobio.2018.11.005. Epub 2018 Nov 20.

PMID:
30554844
50.

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance.

de Klerk DJ, Honeywell RJ, Jansen G, Peters GJ.

Cancers (Basel). 2018 Dec 10;10(12). pii: E503. doi: 10.3390/cancers10120503. Review.

Supplemental Content

Loading ...
Support Center